Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ginkgo Bioworks HoldingsDNA +1.44%62 Days Sales Outstanding is 74.31 as of Jun. 2026, which is 2% below its 10-year median of 75.90. GuruFocus rates DNA with a GF Score™ of 62/100 and a GF Value™ of $5.91 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Ginkgo Bioworks Holdings ranks better than 51.61% on this metric.
Ginkgo Bioworks Holdings (NYSE:DNA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Ginkgo Bioworks Holdings Days Sales Outstanding Related Terms
Ginkgo Bioworks Holdings Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Ginkgo Bioworks Holdings's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginkgo Bioworks Holdings Days Sales Outstanding Chart
DNA vs PBYI, CCCC, RLMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's Days Sales Outstanding falls into.
Ginkgo Bioworks Holdings Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginkgo Bioworks Holdings (DNA) has a Days Sales Outstanding of 74.31 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ginkgo Bioworks Holdings and its competitors. This is near median its historical median of 75.90. Over the past decade, Ginkgo Bioworks Holdings' Days Sales Outstanding has ranged from 31.36 to 86.20. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #407 out of 841 companies in the Biotechnology industry, placing it in the top 48.4%.
Is Ginkgo Bioworks Holdings' Days Sales Outstanding too high?
Ginkgo Bioworks Holdings' current Days Sales Outstanding of 74.31 is near median its 10-year median of 75.90. Over the past 10 years, this metric has ranged from a low of 31.36 to a high of 86.20. The Biotechnology industry median Days Sales Outstanding is 68.98. Ginkgo Bioworks Holdings' value of 74.31 is 7.7% above this industry median. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #407 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Days Sales Outstanding compare to PBYI and CCCC?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #407 out of 841 companies for Days Sales Outstanding. This puts Ginkgo Bioworks Holdings in the upper half of its industry. The industry median Days Sales Outstanding is 68.98. Ginkgo Bioworks Holdings' value of 74.31 is 7.7% above this benchmark. Historically, Ginkgo Bioworks Holdings' own Days Sales Outstanding has ranged from 31.36 to 86.20 over the past decade. While the company's 10-year median is 75.90 vs. the industry median of 68.98, Ginkgo Bioworks Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginkgo Bioworks Holdings's current Days Sales Outstanding of 74.31 is 7.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ginkgo Bioworks Holdings and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginkgo Bioworks Holdings's current Days Sales Outstanding is 74.31, which is near median its own 10-year median of 75.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (DNA) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.91, compared to a current price of $7.03 — trading 19% above its estimated fair value. The current Days Sales Outstanding is 74.31, which is near median its 10-year median of 75.90 and 7.7% above the Biotechnology industry median of 68.98. Ginkgo Bioworks Holdings' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (DNA), the current Days Sales Outstanding is 74.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginkgo Bioworks Holdings (DNA) Overvalued in 2026?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued.
The current stock price of $7.03 is trading 19% above its estimated GF Value™ of $5.91.
GuruFocus considers Ginkgo Bioworks Holdings to be Modestly Overvalued.
Key valuation signals for DNA:
Days Sales Outstanding: 74.31 (near median its 10-year median of 75.90)
GF Value™: $5.91 vs. price of $7.03 (19% above fair value)
Industry Position: 7.7% above the Biotechnology median (#407 of 841)
No single metric tells the full story. See the DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
62GF Score
Get the complete analysis for DNA
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNA has been successfully added to your 
